Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Saul N. Faust, Maguelone Le Roy, Chitsanu Pancharoen, Miguel Angel Rodriguez Weber, Katrina Cathie, Ulrich Behre, Jolanta Bernatoniene, Matthew D. Snape, Klaus Helm, Carlos Eduardo Medina Pech, Ouzama Henry, Carmen Baccarini, Michael Povey, Paul Gillard

ABSTRACT

BACKGROUND: A new formulation of the live-attenuated varicella vaccine Varilrix (GSK) produced without human serum albumin (HSA) was developed to minimize a theoretical risk of transmission of infectious diseases. A previous study showed that the vaccine was immunologically non-inferior to the HSA-containing vaccine and well-tolerated in toddlers; low-grade fever was numerically higher in children receiving the vaccine without HSA, but the study lacked power to conclude on this difference. METHODS: In this phase III, double-blind, multi-center study, healthy 12-23-month-olds were randomized (1:1) to receive two doses of the varicella vaccine without (Var-HSA group) or with HSA (Var + HSA group) at days 0 and 42. The primary objective compared safety of the vaccines in terms of incidence of fever > 39.0 °C in the 15-day period post-first vaccination. The objective was considered met if the upper limit of the 95% confidence interval for the between-group difference in the incidence of fever > 39.0 °C was ≤5% (Var-HSA group minus Var + HSA group). Safety, reactogenicity and immune responses were evaluated. RESULTS: Six hundred fifteen children in the Var-HSA group and 616 in the Var + HSA group received ≥1 vaccination. Fever > 39.0 °C was reported in 3.9 and 5.2% of participants in the Var-HSA and Var + HSA groups, with a between-group difference of - 1.29 (95% confidence interval: - 3.72-1.08); therefore, the primary objective was achieved. Fever rates post-each dose and the incidence of solicited local and general adverse events (AEs) were comparable between groups. Unsolicited AEs were reported for 43.9 and 36.5% of children in the Var-HSA group and 45.8 and 36.0% of children in the Var + HSA group, during 43 days post-dose 1 and 2, respectively. Serious AEs occurred in 2.1% (group Var-HSA) and 2.4% (group Var + HSA) of children, throughout the study. In a sub-cohort of 364 children, all had anti-varicella-zoster virus antibody concentrations ≥50 mIU/mL post-dose 2; comparable geometric mean concentrations were observed between the groups. CONCLUSIONS: The varicella vaccine formulated without HSA did not induce higher rates of fever during the 15 day-post-vaccination period, as compared with the original HSA-containing vaccine. The two vaccines displayed similar safety and immunogenicity profiles in toddlers. TRIAL REGISTRATION: NCT02570126 , registered on 5 October 2015 (www.clinicaltrials.gov). More... »

PAGES

50

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12887-019-1425-7

DOI

http://dx.doi.org/10.1186/s12887-019-1425-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111989384

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30732648


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "NIHR Southampton Clinical Research Facility, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, SO16 6YD, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faust", 
        "givenName": "Saul N.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "GSK, Avenue Fleming 20, B-1300, Wavre, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Roy", 
        "givenName": "Maguelone", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chulalongkorn University", 
          "id": "https://www.grid.ac/institutes/grid.7922.e", 
          "name": [
            "Department of Pediatrics and Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan, 10330, Bangkok, Thailand"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pancharoen", 
        "givenName": "Chitsanu", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Instituto Nacional de Pediatria", 
          "id": "https://www.grid.ac/institutes/grid.419216.9", 
          "name": [
            "Instituto Nacional de Pediatria, Insurgentes Sur 3700C Col. Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weber", 
        "givenName": "Miguel Angel Rodriguez", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "NIHR Southampton Clinical Research Facility, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, SO16 6YD, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cathie", 
        "givenName": "Katrina", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Private Practice, Hauptstrasse 240, 77694, Kehl, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Behre", 
        "givenName": "Ulrich", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol Royal Hospital for Children", 
          "id": "https://www.grid.ac/institutes/grid.415172.4", 
          "name": [
            "Pediatric Infectious Disease Department, Education Centre Level 6, University Hospitals Bristol NHS Foundation Trust, Bristol Royal Hospital for Children, Upper Maudlin Street, BS2 8AE, Bristol, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bernatoniene", 
        "givenName": "Jolanta", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Oxford Vaccine Group, Department of Pediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Headington, OX3 9DU, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Snape", 
        "givenName": "Matthew D.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Private practice, Paulinenstrasse 71a, 32756, Detmold, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Helm", 
        "givenName": "Klaus", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Care and Research SA de CV, Calle 32 No. 217 Col. Garcia Gineres, 97070, M\u00e9rida, Yucat\u00e1n, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Medina Pech", 
        "givenName": "Carlos Eduardo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "GSK, 14200 Shady Grove Rd, 20850, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Henry", 
        "givenName": "Ouzama", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "GSK at the time of study conduct, 160 North Gulph Road, 19406, King of Prussia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baccarini", 
        "givenName": "Carmen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "GSK, Avenue Fleming 20, B-1300, Wavre, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Povey", 
        "givenName": "Michael", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.425090.a", 
          "name": [
            "GSK, Avenue Fleming 20, B-1300, Wavre, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gillard", 
        "givenName": "Paul", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1136/adc.85.2.83", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008224206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12887-016-0546-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019816776", 
          "https://doi.org/10.1186/s12887-016-0546-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12887-016-0546-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019816776", 
          "https://doi.org/10.1186/s12887-016-0546-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/14760584.4.5.629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021946264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/14760584.4.5.629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021946264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1155/2000/647245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034741496"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1542/peds.2008-0939", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039742507"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/0063030-200822060-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046961402", 
          "https://doi.org/10.2165/0063030-200822060-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2004.01.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050456702"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/009286159903300401", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063726059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/009286159903300401", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063726059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078935655", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083247071", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/14760584.2017.1343669", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086151681"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3390/children4090081", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091409979"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: A new formulation of the live-attenuated varicella vaccine Varilrix (GSK) produced without human serum albumin (HSA) was developed to minimize a theoretical risk of transmission of infectious diseases. A previous study showed that the vaccine was immunologically non-inferior to the HSA-containing vaccine and well-tolerated in toddlers; low-grade fever was numerically higher in children receiving the vaccine without HSA, but the study lacked power to conclude on this difference.\nMETHODS: In this phase III, double-blind, multi-center study, healthy 12-23-month-olds were randomized (1:1) to receive two doses of the varicella vaccine without (Var-HSA group) or with HSA (Var\u2009+\u2009HSA group) at days 0 and 42. The primary objective compared safety of the vaccines in terms of incidence of fever >\u200939.0\u2009\u00b0C in the 15-day period post-first vaccination. The objective was considered met if the upper limit of the 95% confidence interval for the between-group difference in the incidence of fever >\u200939.0\u2009\u00b0C was \u22645% (Var-HSA group minus Var\u2009+\u2009HSA group). Safety, reactogenicity and immune responses were evaluated.\nRESULTS: Six hundred fifteen children in the Var-HSA group and 616 in the Var\u2009+\u2009HSA group received \u22651 vaccination. Fever >\u200939.0\u2009\u00b0C was reported in 3.9 and 5.2% of participants in the Var-HSA and Var\u2009+\u2009HSA groups, with a between-group difference of -\u20091.29 (95% confidence interval: -\u20093.72-1.08); therefore, the primary objective was achieved. Fever rates post-each dose and the incidence of solicited local and general adverse events (AEs) were comparable between groups. Unsolicited AEs were reported for 43.9 and 36.5% of children in the Var-HSA group and 45.8 and 36.0% of children in the Var\u2009+\u2009HSA group, during 43\u2009days post-dose 1 and 2, respectively. Serious AEs occurred in 2.1% (group Var-HSA) and 2.4% (group Var\u2009+\u2009HSA) of children, throughout the study. In a sub-cohort of 364 children, all had anti-varicella-zoster virus antibody concentrations \u226550 mIU/mL post-dose 2; comparable geometric mean concentrations were observed between the groups.\nCONCLUSIONS: The varicella vaccine formulated without HSA did not induce higher rates of fever during the 15\u2009day-post-vaccination period, as compared with the original HSA-containing vaccine. The two vaccines displayed similar safety and immunogenicity profiles in toddlers.\nTRIAL REGISTRATION: NCT02570126 , registered on 5 October 2015 (www.clinicaltrials.gov).", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12887-019-1425-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024635", 
        "issn": [
          "1471-2431"
        ], 
        "name": "BMC Pediatrics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study", 
    "pagination": "50", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6441c49aef03f8f2f22484b4cd6b5f138a5acc754dcab3a8e9bdbcaef5d40ebc"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30732648"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967804"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12887-019-1425-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111989384"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12887-019-1425-7", 
      "https://app.dimensions.ai/details/publication/pub.1111989384"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000338_0000000338/records_47975_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12887-019-1425-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12887-019-1425-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12887-019-1425-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12887-019-1425-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12887-019-1425-7'


 

This table displays all metadata directly associated to this object as RDF triples.

208 TRIPLES      21 PREDICATES      41 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12887-019-1425-7 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N81e1dad9b1734680bb6976772ab02afc
4 schema:citation sg:pub.10.1186/s12887-016-0546-5
5 sg:pub.10.2165/0063030-200822060-00005
6 https://app.dimensions.ai/details/publication/pub.1078935655
7 https://app.dimensions.ai/details/publication/pub.1083247071
8 https://doi.org/10.1016/j.vaccine.2004.01.016
9 https://doi.org/10.1080/14760584.2017.1343669
10 https://doi.org/10.1136/adc.85.2.83
11 https://doi.org/10.1155/2000/647245
12 https://doi.org/10.1177/009286159903300401
13 https://doi.org/10.1542/peds.2008-0939
14 https://doi.org/10.1586/14760584.4.5.629
15 https://doi.org/10.3390/children4090081
16 schema:datePublished 2019-12
17 schema:datePublishedReg 2019-12-01
18 schema:description BACKGROUND: A new formulation of the live-attenuated varicella vaccine Varilrix (GSK) produced without human serum albumin (HSA) was developed to minimize a theoretical risk of transmission of infectious diseases. A previous study showed that the vaccine was immunologically non-inferior to the HSA-containing vaccine and well-tolerated in toddlers; low-grade fever was numerically higher in children receiving the vaccine without HSA, but the study lacked power to conclude on this difference. METHODS: In this phase III, double-blind, multi-center study, healthy 12-23-month-olds were randomized (1:1) to receive two doses of the varicella vaccine without (Var-HSA group) or with HSA (Var + HSA group) at days 0 and 42. The primary objective compared safety of the vaccines in terms of incidence of fever > 39.0 °C in the 15-day period post-first vaccination. The objective was considered met if the upper limit of the 95% confidence interval for the between-group difference in the incidence of fever > 39.0 °C was ≤5% (Var-HSA group minus Var + HSA group). Safety, reactogenicity and immune responses were evaluated. RESULTS: Six hundred fifteen children in the Var-HSA group and 616 in the Var + HSA group received ≥1 vaccination. Fever > 39.0 °C was reported in 3.9 and 5.2% of participants in the Var-HSA and Var + HSA groups, with a between-group difference of - 1.29 (95% confidence interval: - 3.72-1.08); therefore, the primary objective was achieved. Fever rates post-each dose and the incidence of solicited local and general adverse events (AEs) were comparable between groups. Unsolicited AEs were reported for 43.9 and 36.5% of children in the Var-HSA group and 45.8 and 36.0% of children in the Var + HSA group, during 43 days post-dose 1 and 2, respectively. Serious AEs occurred in 2.1% (group Var-HSA) and 2.4% (group Var + HSA) of children, throughout the study. In a sub-cohort of 364 children, all had anti-varicella-zoster virus antibody concentrations ≥50 mIU/mL post-dose 2; comparable geometric mean concentrations were observed between the groups. CONCLUSIONS: The varicella vaccine formulated without HSA did not induce higher rates of fever during the 15 day-post-vaccination period, as compared with the original HSA-containing vaccine. The two vaccines displayed similar safety and immunogenicity profiles in toddlers. TRIAL REGISTRATION: NCT02570126 , registered on 5 October 2015 (www.clinicaltrials.gov).
19 schema:genre research_article
20 schema:inLanguage en
21 schema:isAccessibleForFree true
22 schema:isPartOf N38d6d0198cfc41ee9e8c36e382c5f4ad
23 N4a47fdb703434ed5ad7f81d4e55b51c8
24 sg:journal.1024635
25 schema:name Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study
26 schema:pagination 50
27 schema:productId N063747e4f8d54decb8617822cc35cb62
28 N2932f1cc6646498b97be579a3aa48646
29 N2c331d4c925e421ea3d35593ec5f3cd5
30 N67165af7f06a40928fddf3b321469f5b
31 N7a4943fe8fdc46b68e2314d8f51737d0
32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111989384
33 https://doi.org/10.1186/s12887-019-1425-7
34 schema:sdDatePublished 2019-04-11T09:11
35 schema:sdLicense https://scigraph.springernature.com/explorer/license/
36 schema:sdPublisher Nd1f49a2ebc1349e2bf0a466d589bb262
37 schema:url https://link.springer.com/10.1186%2Fs12887-019-1425-7
38 sgo:license sg:explorer/license/
39 sgo:sdDataset articles
40 rdf:type schema:ScholarlyArticle
41 N05d1e625db40453289abf23a45909724 rdf:first Nef240b54c6e041659c6eeb1e3a29f288
42 rdf:rest N2b8356b732d746488b8d0c449ebc742a
43 N063747e4f8d54decb8617822cc35cb62 schema:name dimensions_id
44 schema:value pub.1111989384
45 rdf:type schema:PropertyValue
46 N0a1ef05bcf6f4642a4ea1510fcd22986 rdf:first N5d2b9de8a0d543d4b60a5a12d279f7a7
47 rdf:rest N83aa150db3594cd38dca75c92b91a854
48 N1607ee393cd34f70ab691f96ade6a556 schema:name Medical Care and Research SA de CV, Calle 32 No. 217 Col. Garcia Gineres, 97070, Mérida, Yucatán, Mexico
49 rdf:type schema:Organization
50 N17760635086f409bb9be93502af851a4 schema:name Private practice, Paulinenstrasse 71a, 32756, Detmold, Germany
51 rdf:type schema:Organization
52 N17c51df024fd41b1b73e3cefefd867cc rdf:first Nb0145de91a1647bdac8df66d025f5323
53 rdf:rest N3026d409762844e0b05c49ca39a90953
54 N1ff0af94e6094388b625b8877c49e7e8 schema:name NIHR Southampton Clinical Research Facility, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, SO16 6YD, Southampton, UK
55 rdf:type schema:Organization
56 N2932f1cc6646498b97be579a3aa48646 schema:name readcube_id
57 schema:value 6441c49aef03f8f2f22484b4cd6b5f138a5acc754dcab3a8e9bdbcaef5d40ebc
58 rdf:type schema:PropertyValue
59 N2ad3de8837844834aec145d268b8fde5 schema:affiliation https://www.grid.ac/institutes/grid.425090.a
60 schema:familyName Povey
61 schema:givenName Michael
62 rdf:type schema:Person
63 N2b8356b732d746488b8d0c449ebc742a rdf:first N6a556603b78c45649781541b2ab73767
64 rdf:rest N0a1ef05bcf6f4642a4ea1510fcd22986
65 N2c331d4c925e421ea3d35593ec5f3cd5 schema:name nlm_unique_id
66 schema:value 100967804
67 rdf:type schema:PropertyValue
68 N2d83143b89c2477793a3810b0cea8107 schema:name Private Practice, Hauptstrasse 240, 77694, Kehl, Germany
69 rdf:type schema:Organization
70 N3026d409762844e0b05c49ca39a90953 rdf:first Nb6bcee1e308c4f3fb7544f3782e5fa81
71 rdf:rest N6fe67705b2834323a9d9d603edb349ca
72 N38d6d0198cfc41ee9e8c36e382c5f4ad schema:volumeNumber 19
73 rdf:type schema:PublicationVolume
74 N4a47fdb703434ed5ad7f81d4e55b51c8 schema:issueNumber 1
75 rdf:type schema:PublicationIssue
76 N5250ba037ee34c4fb749f073ddb44b4e schema:affiliation N1ff0af94e6094388b625b8877c49e7e8
77 schema:familyName Faust
78 schema:givenName Saul N.
79 rdf:type schema:Person
80 N5c5238df01e147899bfff50e872164f4 rdf:first Nc8e393f3364f45baa91b8c50f70a22d1
81 rdf:rest Na0a026c924284697996ce15020ce0eeb
82 N5cc3d3150fda41c5b1a8fed5ce0b578d schema:name GSK, 14200 Shady Grove Rd, 20850, Rockville, MD, USA
83 rdf:type schema:Organization
84 N5d2b9de8a0d543d4b60a5a12d279f7a7 schema:affiliation N1607ee393cd34f70ab691f96ade6a556
85 schema:familyName Medina Pech
86 schema:givenName Carlos Eduardo
87 rdf:type schema:Person
88 N610772a0b3844259b5d22284c617ecab rdf:first N67681c871acc47768c6e49caf72f05bb
89 rdf:rest N17c51df024fd41b1b73e3cefefd867cc
90 N67165af7f06a40928fddf3b321469f5b schema:name doi
91 schema:value 10.1186/s12887-019-1425-7
92 rdf:type schema:PropertyValue
93 N67681c871acc47768c6e49caf72f05bb schema:affiliation https://www.grid.ac/institutes/grid.7922.e
94 schema:familyName Pancharoen
95 schema:givenName Chitsanu
96 rdf:type schema:Person
97 N6a556603b78c45649781541b2ab73767 schema:affiliation N17760635086f409bb9be93502af851a4
98 schema:familyName Helm
99 schema:givenName Klaus
100 rdf:type schema:Person
101 N6fe09d427a054443b7f28fe3f30f4f7c rdf:first Nbb936f174200415badc7a20812537b7a
102 rdf:rest N610772a0b3844259b5d22284c617ecab
103 N6fe67705b2834323a9d9d603edb349ca rdf:first Nf68d727b05014ded8e33558dfe5c62fc
104 rdf:rest N93de93e29e9c4533908795e7709ab5aa
105 N7a4943fe8fdc46b68e2314d8f51737d0 schema:name pubmed_id
106 schema:value 30732648
107 rdf:type schema:PropertyValue
108 N81e1dad9b1734680bb6976772ab02afc rdf:first N5250ba037ee34c4fb749f073ddb44b4e
109 rdf:rest N6fe09d427a054443b7f28fe3f30f4f7c
110 N83aa150db3594cd38dca75c92b91a854 rdf:first Na2ef629a4c464be5bb302d8fa1ede8c3
111 rdf:rest N5c5238df01e147899bfff50e872164f4
112 N93de93e29e9c4533908795e7709ab5aa rdf:first Na2186b5326dc4deb8bd45d3c9c5d74c8
113 rdf:rest N05d1e625db40453289abf23a45909724
114 Na0a026c924284697996ce15020ce0eeb rdf:first N2ad3de8837844834aec145d268b8fde5
115 rdf:rest Na687d74ed4f04333af0960f5133c5a48
116 Na2186b5326dc4deb8bd45d3c9c5d74c8 schema:affiliation https://www.grid.ac/institutes/grid.415172.4
117 schema:familyName Bernatoniene
118 schema:givenName Jolanta
119 rdf:type schema:Person
120 Na2ef629a4c464be5bb302d8fa1ede8c3 schema:affiliation N5cc3d3150fda41c5b1a8fed5ce0b578d
121 schema:familyName Henry
122 schema:givenName Ouzama
123 rdf:type schema:Person
124 Na687d74ed4f04333af0960f5133c5a48 rdf:first Nb88e3d22818e4e5ca656e6d31e21ef93
125 rdf:rest rdf:nil
126 Naac45a07280e4d089a4ebde47235474d schema:name NIHR Southampton Clinical Research Facility, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, SO16 6YD, Southampton, UK
127 rdf:type schema:Organization
128 Nb0145de91a1647bdac8df66d025f5323 schema:affiliation https://www.grid.ac/institutes/grid.419216.9
129 schema:familyName Weber
130 schema:givenName Miguel Angel Rodriguez
131 rdf:type schema:Person
132 Nb6bcee1e308c4f3fb7544f3782e5fa81 schema:affiliation Naac45a07280e4d089a4ebde47235474d
133 schema:familyName Cathie
134 schema:givenName Katrina
135 rdf:type schema:Person
136 Nb88e3d22818e4e5ca656e6d31e21ef93 schema:affiliation https://www.grid.ac/institutes/grid.425090.a
137 schema:familyName Gillard
138 schema:givenName Paul
139 rdf:type schema:Person
140 Nbb936f174200415badc7a20812537b7a schema:affiliation https://www.grid.ac/institutes/grid.425090.a
141 schema:familyName Le Roy
142 schema:givenName Maguelone
143 rdf:type schema:Person
144 Nc8e393f3364f45baa91b8c50f70a22d1 schema:affiliation https://www.grid.ac/institutes/grid.418019.5
145 schema:familyName Baccarini
146 schema:givenName Carmen
147 rdf:type schema:Person
148 Nd1f49a2ebc1349e2bf0a466d589bb262 schema:name Springer Nature - SN SciGraph project
149 rdf:type schema:Organization
150 Nef240b54c6e041659c6eeb1e3a29f288 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
151 schema:familyName Snape
152 schema:givenName Matthew D.
153 rdf:type schema:Person
154 Nf68d727b05014ded8e33558dfe5c62fc schema:affiliation N2d83143b89c2477793a3810b0cea8107
155 schema:familyName Behre
156 schema:givenName Ulrich
157 rdf:type schema:Person
158 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
159 schema:name Medical and Health Sciences
160 rdf:type schema:DefinedTerm
161 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
162 schema:name Public Health and Health Services
163 rdf:type schema:DefinedTerm
164 sg:journal.1024635 schema:issn 1471-2431
165 schema:name BMC Pediatrics
166 rdf:type schema:Periodical
167 sg:pub.10.1186/s12887-016-0546-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019816776
168 https://doi.org/10.1186/s12887-016-0546-5
169 rdf:type schema:CreativeWork
170 sg:pub.10.2165/0063030-200822060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046961402
171 https://doi.org/10.2165/0063030-200822060-00005
172 rdf:type schema:CreativeWork
173 https://app.dimensions.ai/details/publication/pub.1078935655 schema:CreativeWork
174 https://app.dimensions.ai/details/publication/pub.1083247071 schema:CreativeWork
175 https://doi.org/10.1016/j.vaccine.2004.01.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050456702
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1080/14760584.2017.1343669 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086151681
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1136/adc.85.2.83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008224206
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1155/2000/647245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034741496
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1177/009286159903300401 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063726059
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1542/peds.2008-0939 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039742507
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1586/14760584.4.5.629 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021946264
188 rdf:type schema:CreativeWork
189 https://doi.org/10.3390/children4090081 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091409979
190 rdf:type schema:CreativeWork
191 https://www.grid.ac/institutes/grid.415172.4 schema:alternateName Bristol Royal Hospital for Children
192 schema:name Pediatric Infectious Disease Department, Education Centre Level 6, University Hospitals Bristol NHS Foundation Trust, Bristol Royal Hospital for Children, Upper Maudlin Street, BS2 8AE, Bristol, UK
193 rdf:type schema:Organization
194 https://www.grid.ac/institutes/grid.418019.5 schema:alternateName GlaxoSmithKline (United States)
195 schema:name GSK at the time of study conduct, 160 North Gulph Road, 19406, King of Prussia, PA, USA
196 rdf:type schema:Organization
197 https://www.grid.ac/institutes/grid.419216.9 schema:alternateName Instituto Nacional de Pediatria
198 schema:name Instituto Nacional de Pediatria, Insurgentes Sur 3700C Col. Insurgentes Cuicuilco, Coyoacan, 04530, Mexico City, Mexico
199 rdf:type schema:Organization
200 https://www.grid.ac/institutes/grid.425090.a schema:alternateName GlaxoSmithKline (Belgium)
201 schema:name GSK, Avenue Fleming 20, B-1300, Wavre, Belgium
202 rdf:type schema:Organization
203 https://www.grid.ac/institutes/grid.4991.5 schema:alternateName University of Oxford
204 schema:name Oxford Vaccine Group, Department of Pediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Headington, OX3 9DU, Oxford, UK
205 rdf:type schema:Organization
206 https://www.grid.ac/institutes/grid.7922.e schema:alternateName Chulalongkorn University
207 schema:name Department of Pediatrics and Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan, 10330, Bangkok, Thailand
208 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...